Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR)
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
- 试验地点
- 2
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
This is a phase II, prospective, single arm, non comparative study with crizotinib combined with bevacizumab in treatment-naive lung adenocarcinoma cancer patients with ALK translocation or ROS1 translocation or MET amplification
详细描述
This is a phase II, prospective, single arm, non comparative study with crizotinib combined with bevacizumab in treatment-naive lung adenocarcinoma cancer patients with ALK translocation or ROS1 translocation or MET amplification. Patients with locally advanced or metastatic NSCLC(Stage ⅢB/ⅢC/Ⅳ) with at least one measurable tumor lesion will be considered eligible for the trial. All potentially eligible patients will be evaluated for ALK、MET and ROS1 by FISH or IHC or NGS to detect MET amplification or ALK translocation or ROS1 translocation After evaluation of inclusion and exclusion criteria, and after signature of informed consent form, all MET amplified or ALK translocation or ROS1 translocated eligible patients will receive crizotinib 250 mg BID p.o and bevacizumab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of lung adenocarcinoma cancer
- •Availability of tumor tissue for ROS1, ALK, MET analyses
- •EGFR was wild type, positive for ROS1 translocation or ALK translocation or MET amplification
- •At least one radiological measurable disease according to RECIST criteria (Response Evaluation Criteria in Solid Tumors )
- •Patient didn't received any therapy for lung cancer before except surgery or radiotherapy, or the adjuvant chemotherapy had stopped for more than 12 months
- •Performance status 0-2 (ECOG)
- •Patient compliance to trial procedures
- •age ≥ 18 years
- •Written informed consent
- •Adequate BM function (ANC ≥ 1.5x109/L, Platelets ≥ 100x109/L, HgB > 9g/dl)
- •Adequate liver function (bilirubin <G2, transaminases no more than 3xULN/<5xULN in present of liver metastases).
- •Normal level of alkaline phosphatase and creatinine.
- •If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of approved contraceptive method [intrauterine contraceptive device (IUD), birth control pills, or barrier device] during and for ninety(90) days after end of treatment.
排除标准
- •Patients with EGFR mutation
- •No tumor tissue available or patient negative for ALK translocation or ROS1 translocation or MET amplification
- •Absence of any measurable lesion
- •Prior therapy with bevacizumab or ipilimumab
- •Symptomatic brain metastases
- •Previous radiotherapy on the target lesion(s). If all sites were included in radiotherapy fields patient is eligible only if there is evidence of progressive disease after completion of radiotherapy.
- •Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uteri and squamous cell carcinoma of the skin
- •Pregnancy or lactating
- •Other serious illness or medical condition potentially interfering with the study
- •Significant known vascular disease
- •Symptomatic peripheral vascular disease
- •Evidence of bleeding diathesis or coagulopathy
- •Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment
- •Serious, non-healing wound, ulcer or bone fracture
- •Proteinuria at screening
- •Known hypersensitivity to any component of bevacizumab
- •History of hemoptysis within 3 months prior to study enrollment
- •Current, ongoing treatment with full-dose warfarin or its equivalent
研究组 & 干预措施
Patients with ALK translocation
Treatment-naive lung adenocarcinoma cancer patients with ALK translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
干预措施: Crizotinib, bevacizumab (Drug)
Patients with ROS1 translocation
Treatment-naive lung adenocarcinoma cancer patients with ROS1 translocation with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
干预措施: Crizotinib, bevacizumab (Drug)
Patients with MET amplification
Treatment-naive lung adenocarcinoma cancer patients with MET amplication with locally advanced or metastatic lung adenocarcinoma cancer and with at least one measurable tumor lesion will be considered eligible for the trial and they will receive crizotinib 250 mg BID p.o combined with bevacizomab 7.5mg/kg every three weeks until disease progression, unacceptable toxicity or patient refusal
干预措施: Crizotinib, bevacizumab (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months
次要结局
- Response rate in patients with ALK translocation or ROS1 translocation or MET amplification(From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months)
- Toxicity analysis: Incidence of Grade 3-4 Grade Toxicity graded according to National Cancer(From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months)
- Overall Survival (OS)(From date of the first enrolment until the date of last documented progression or date of death from any cause, assessed up to 100 months)
研究者
yihu
Director of oncology department
Chinese PLA General Hospital